The World Congress on Targeting Metabesity 2017

The World Congress on Targeting Metabesity 2017 is dedicated to major diseases and conditions to shared metabolic roots, including diabetes, obesity, and cardiovascular diseases.

Topics

• Cancer
  • Validated targets
  • Metabolic pathways and signaling
  • Utility of animal models
  • Animal study results
  • Genomic and other means of high risk identification
  • Evaluation of current and novel candidate interventions (nutritional, pharmacologic, life style)
  • Epidemiology analysis and studies
  • Clinical studies
  • Meta-analyses of clinical studies and lessons learned from chemoprevention trials
• Aging and Sarcopenia
  • Genomic and other means of high risk identification
  • Metabolic pathways and signaling
  • Animal model studies
  • Validation of targets
  • Methods to interpret translatability of animal results
  • Evaluation of candidate interventions (nutritional, pharmacologic, life style)
  • Proposed clinical design approaches
  • Clinical efficacy endpoints validation (functional and person-reported instruments)
  • Epidemiology analysis and studies
  • New clinical study results
  • Specific bioethical considerations
  • Comparison of major regulatory positions
• Neurodegeneration
  • Validation of targets
  • Metabolic pathway and signaling
  • Methods to enhance translation of animal results
  • Animal model studies
  • Proposed clinical design approaches
  • Clinical efficacy endpoints validation
  • Comparison of major regulatory positions
  • Clinical studies
• Diabetes
  • Islet biology (embryogenesis and homeostasis of islet mass and function)
  • Metabolic pathway and signaling
  • Validation of metabolic, inflammatory, and immunologic targets
  • Immunity (pathogenesis and interventions)
  • Methods to enhance translation of animal results
  • Animal model studies
  • Clinical efficacy endpoints validation
  • Genomic and other means of high risk identification
  • Clinical studies
  • Proposed clinical design approaches
  • Lessons learned from T1D and T2D prevention trials
  • New analyses of reported clinical trials
  • Comparison of major regulatory positions
• Metabesity-general approaches and tools
  • Animal model development
  • Metabesity pathways and signaling (choke points and pleotropic agents that leverage 2 or more major clinical outcomes)
  • Efficacy endpoints-functional, quality life survival, person-reported
  • Biomarkers and imaging
  • General issues related to repurposing approved therapies
  • Microbiome (mechanisms, characterization, interventions)
  • Biostatistical methods
  • Acquiring and managing big data
  • Regulatory approaches
  • Cost-effectiveness approaches relevant to payors and policy makers
  • Education
  • "Apps" and other engagement and tracking tools
  • Bioethics
  • Econometrics
  • Public policy and public health approaches

Who should Attend

• R&D personnel
• Medical Professionals
• Regulatory Affairs specialists
• CEOs
• CRAs
• CROs
• Research facility managers
• QA personnel
• Start-up Companies
• Pharmaceutical Company representatives